Platform
Thyas’ platform: We Regenerate Your Immune System
Thyas owns proprietary iPSC-derived immune cell platform and continuously generates Immune cell products
Various Immune Cells derived from Allogeneic iPSC
iTCR-T (iPSC-derived TCR-T)
Thyas’ next-gen iTCR-T
Thyas develops personalized iTCR-T for the next-generation iTCR-T to target personalized antigens (including neoantigens) and expand the patient applicability- 1Selection of Activated T cells with a specific marker
- 2Quick acquisition of selected TCRs
- 3Personalized iPS-TCR-T (2nd Generation iTCR-T)
Characteristics
iPS-T Eliminates Tumor Cells while Proliferating
Exhausted parental T cells
Black：Parental T Cell Clone (Exhausted)
Green：Antigen X positive tumors
(Black cells can not kill green cells well)
iPS-T
Black：iPSC-derived CD8a+b+T cells (Rejuvenated)
Green： Antigen X positive tumors
(Black cells kill green cells while
proliferating)
Molecular Therapy (2021), doi: https://doi.org/10.1016/ j.ymthe.2021.05.016.
iPS-T Demonstrates Specific Cytotoxicity against Tumor Cells
iPS-Ts only attack the targeted cancer cells.
Red ： iPS-T specific to antigen X
Green： Tumor cells NOT expressing antigen X
(iPS-T patrols but does not attack
the tumor cells)
Red ： iPS-T specific to antigen X
Green： Tumor cells expressing antigen X
(iPS-T attacks and eliminates
the tumor cells)
Cell Stem Cell | (2018) 23:1–9 | https://doi.org/10.1016/j.stem.2018.10.005
iPS-T is CD8α+β+ T cells
- iPS-T expresses CD8α+β+.
- iPS-T has high avidity to target antigens (adaptive immunity) while CD8α+α+ T cells have low avidity to them (innate immunity).
CD8αβ
Strong TCR signals
for antigen specific cytotoxicity
CD8αα
Insufficient TCR signals
for antigen specific cytotoxicity
Cell Stem Cell | (2018) 23:1–9 | https://doi.org/10.1016/j.stem.2018.10.005
iPS-T Regains Naive T Cell Phenotype
- Memory T cells play a key role in immune surveillance and long-term immunity.
- It is reported clinical efficacy of immune checkpoint inhibitors, or CAR-T has a strong positive correlation with the proportion of memory/naive T cells in patients’ body.
iPS-T is Proliferative as Naïve T cells
- iPS-T has longer telomere than parental T cells.
Elongation of iPS-T‘s telomere
Correlation between the efficacy of T cell therapy
and the telomere length is reported.
Nat Rev Cancer | (2008) 8: 299–308 | https://doi.org/10.1038/nrc2355
iPS-T‘s high ability of proliferation
Exhausted T cells do not proliferate well,
while iPS-T shows massive growth
as naïve T cells do.
iPS-T Reduces Expression of Exhaustion Markers
- iPS-T has no/low expression of exhaustion markers unlike patients’ exhausted T cells.
Patient’s exhausted T cell
When immune checkpoint receptors on
T cells are activated, cytotoxic responses of
T cells are suppressed.
iPS-T
As iPS-T cells express no/less
immune
check points receptors,
potent cytotoxic responses
against tumor cells are regained.
Pipeline
※Please scroll left and right to see.